Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials
Collaboration leverages Medidata AI to improve access and participation of diverse population groups in clinical studies
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced a partnership with Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.
Fortrea’s use of Medidata AI builds on an existing collaboration between the two companies, expanding on Fortrea's use of Medidata Rave EDC, an advanced, robust, and secure EDC system for clinical trial site, patient and lab data capture and management. Fortrea will leverage features of Medidata AI Intelligent Trials, including study feasibility and diversity data, to help emerging and large biopharmas, as well as medical device and diagnostic companies, achieve enrollment goals that reflect the populations most impacted by each disease or condition under study.
"Medidata’s data and interface capabilities will enhance our ability to seamlessly integrate diverse populations into the clinical trial process,” said Fortrea COO and President of Clinical Services Mark Morais. “We are thrilled to work with Medidata as part of Fortrea’s go-forward data strategy.”
“Fortrea and Medidata share a commitment to advancing clinical trial research and this partnership is poised to reshape the landscape of diversity in clinical trials globally,” said Fareed Melhem, SVP, Medidata AI. “Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals.”
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of approximately 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Opjustering af forventninger 2023 og resultatforventninger 20247.12.2023 16:47:03 CET | pressemeddelelse
Nordfyns Bank koncernen opjusterer forventningerne for hele 2023 til et resultat før skat i niveauet 120 - 140 mio. kr. fra tidligere udmeldte forventninger om et resultat før skat i niveauet 95 - 115 mio. kr. Opjusteringen sker som følge af højere kursreguleringer samt et lavere nedskrivningsbehov. Samtidigt meddeles det, at Nordfyns Bank koncernen forventer for 2024 at opnå et resultat før skat, som vil ligge i niveauet 70 - 100 mio. kr. Forventningerne er forbundet med usikkerhed og afhænger blandt andet af den fremtidige samfundsmæssige økonomiske udvikling, herunder udviklingen i det generelle renteniveau, kursreguleringer som følge af udviklingen på de finansielle markeder, samt udviklingen i nedskrivningsbehovet. Venlig hilsen Nordfyns Bank Vedhæftet fil Meddelelse_nr12_2023
Eimskip: Transaction by a person closely associated with a PDMR7.12.2023 16:44:43 CET | Press release
Please find attached notifications regarding transactions by a person closely associated with a PDMR of Eimskipafélag Íslands hf., cf. Art. 19 of MAR regulation. Further information can be found in the attached notifications. Attachments Sjávarlind til Kauphallar 1Sjávarlind til Kauphallar 2
Finanskalender 20247.12.2023 16:10:04 CET | pressemeddelelse
Bestyrelsen har vedtaget følgende terminer for offentliggørelse af regnskabsmeddelelser og afholdelse af ordinær generalforsamling: Årsregnskab 202314. marts 2024Periodemeddelelse17. april 2024Generalforsamling17. april 2024Periodemeddelelse22. august 2024Periodemeddelelse24. oktober 2024 Bemærk venligst, at seneste frist for fremsættelse af krav om optagelse af et bestemt emne på dagsordenen, er seks uger før afholdelsen af årets generalforsamling (§ 7.2 i selskabets vedtægter). Emner, der ønskes optaget på årets generalforsamling, skal således være selskabet skriftligt i hænde senest onsdag den 5. marts 2024. Med venlig hilsen Torben Schultz Administrerende direktør For yderligere oplysninger venligst kontakt Adm. direktør Torben Schultz, 40 10 28 76 Vedhæftet fil Meddelelse nr 10 i 2023 (finanskalender 2024)
Update on re-sale of unsecured bonds held in treasury and share buyback7.12.2023 15:37:23 CET | Press release
Golar LNG Limited (“Golar” or the “Company”) announces that it has recently re-sold $30.5 million notional value of its senior unsecured bonds maturing 20 October 2025 (ISIN NO0011123432) which were previously held in treasury. Following the sale, Golar maintains $130.6 million notional value of unsecured bonds in treasury. The Company also provides an update on its previously announced share buyback program with total approved amount of up to $150.0 million. Since 30 September 2023, the company has bought back a total of 1,126,682 shares. Upon cancellation of these shares, the total number of outstanding shares will be reduced to 104,798,000. Of the $150.0 million approved share buyback scheme, $92.9 million remains available for further repurchases which will continue to be opportunistically pursued. Golar LNG Limited Hamilton, Bermuda December 7, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Directorate change7.12.2023 15:17:27 CET | Press release
Volta Finance Limited (VTA/VTAS) Directorate Change NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Guernsey, 7 December 2023 Retirement of director The Board announces that Mr Graham Harrison, a non-executive director and Chair of the Management Engagement Committee of the Company, has retired from the Board with effect from 6 December 2023. Mr Harrison has been on the Board since October 2015, and the Directors would like to express their gratitude for his valuable contribution during his tenure. Upon the retirement of Mr Harrison, the Board has approved the appointment of Mrs Joanne Peacegood, a non-executive director, to the role of Chair of the Management Engagement Committee. CONTACTS Company Secretary and Administrator BNP Paribas S.A, Guernsey Branch email@example.com +44 (0) 1481 750 853 Corporate Broker Cavendish Securities plc Andrew Worne Daniel Balabanoff +44 (0) 20 7397 8900 ***** ABOUT VOLTA FINANCE L